1715P the Landscape of SMAD4 Alteration in Chinese Solid Tumor Patients
H. Xu,X. Liu,Y. Zhang,C. Liu,F. Meng,P. Du,L. Li
DOI: https://doi.org/10.1016/j.annonc.2022.07.1793
IF: 51.769
2022-01-01
Annals of Oncology
Abstract:SMAD4 mutations have been associated with worse prognosis and metastatic disease in patients with various cancers. The differences in mutation profiles of SMAD4 gene in pan-cancer can help understand pathogenesis, prognosis, and identify targets for therapy. Using commercial NGS assays, we retrospectively analyzed genomic DNA alterations in normal-paired samples from 3957 patients with malignancies between 2019 to 2022, and alterations including single-base substitution, short and long insertion/deletions, copy number variations, gene fusions and rearrangements. SMAD4 gene was altered in 6.7% (264 of 3957) of all solid tumors. The frequency of SMAD4 variations was assessed in multiple cancer types, including pancreatic cancer 20.5% (30/146), colorectal cancer 18.7% (122/654), cholangiocarcinoma 11.3% (15/133), cervix tumor 5.8% (3/52), cervical cancer 3.4% (4/117), liver cancer 3.2% (7/221), gastric carcinoma 3.1% (12/386), breast cancer 2.2% (1/45), non-small cell lung cancer 1.7% (26/1512), renal carcinoma 1.3% (1/77) and ovarian cancer 1% (1/135). Furthermore, in our cohort, A total 347 genetic alterations were identified in 264 patients, including 188 missense (54.2%), 56 nonsense (16.1%), 43 frameshift (13.3%), 37 copy number alterations (10.7%), 12 splicing (3.5%), 8 deletion (2.3%), 2 insertion (0.6%) and 1 stop-loss (0.3%). Among these patients, 10.2% (27/264) of patients had metastatic disease at the time of initial biopsy, including colorectal cancer 48.1% (13/27), pancreatic cancer 33.3% (9/27), gastric carcinoma 7.4% (2/27), non-small cell lung cancer 7.4% (2/27) and cholangiocarcinoma 3.7% (1/27). SMAD4 deleterious mutations are highly diverse and present at low to moderate frequencies across many cancers. SMAD4 mutations may represent a more sensitive biomarker to identify patients at greater risk for developing metastatic disease and are likely involved in the transformation from localized to metastatic disease.